Ingolf Cascorbi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3440596/publications.pdf

Version: 2024-02-01

237 papers	13,497 citations	18482 62 h-index	28297 105 g-index
260 all docs	260 docs citations	260 times ranked	13008 citing authors

#	Article	IF	Citations
1	Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3473-3478.	7.1	1,099
2	Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clinical Pharmacology and Therapeutics, 2001, 69, 169-174.	4.7	628
3	Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. , 2006, 112, 457-473.		319
4	Deposition of Alzheimer's ??-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics and Genomics, 2002, 12, 535-541.	5.7	311
5	Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology, 2003, 124, 26-33.	1.3	309
6	Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clinical Pharmacology and Therapeutics, 2002, 72, 584-594.	4.7	279
7	Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. Molecular Psychiatry, 2005, 10, 220-224.	7.9	256
8	MDR1â€Pâ€Glycoprotein (ABCB1) Mediates Transport of Alzheimerâ€™s Amyloidâ€Î² Peptidesâ€”Implications for the Mechanisms of Aβ Clearance at the Bloodâ€“Brain Barrier. Brain Pathology, 2007, 17, 347-353.	4.1	216
9	Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. European Journal of Clinical Pharmacology, 2003, 59, 303-312.	1.9	212
10	Functional Gene Variants of CYP3A4. Clinical Pharmacology and Therapeutics, 2014, 96, 340-348.	4.7	192
11	Should We Use N -Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?. Antimicrobial Agents and Chemotherapy, 2005, 49, 1733-1738.	3.2	187
12	CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis, 2003, 24, 875-882.	2.8	184
13	The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clinical Pharmacology and Therapeutics, 2002, 72, 572-583.	4.7	183
14	Association of Liver Injury From Specific Drugs, or Groups ofÂDrugs, With Polymorphisms in HLA and Other Genes in aÂGenome-Wide Association Study. Gastroenterology, 2017, 152, 1078-1089.	1.3	174
15	Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes*. Clinical Pharmacology and Therapeutics, 2002, 72, 326-332.	4.7	172
16	P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations. Handbook of Experimental Pharmacology, 2011, , 261-283.	1.8	162
17	The Role of P-glycoprotein in Cerebral Amyloid Angiopathy; Implications for the Early Pathogenesis of Alzheimers Disease. Current Alzheimer Research, 2004, 1, 121-125.	1.4	154
18	CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis, 2002, 23, 1969-1977.	2.8	153

#	Article	IF	Citations
19	Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nature Communications, 2014, 5, 4757.	12.8	153
20	Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clinical Pharmacology and Therapeutics, 2004, 76, 192-200.	4.7	150
21	Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis, 2000, 21, 35-41.	2.8	149
22	Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics Journal, 2007, 7, 56-65.	2.0	148
23	VARIABLE EXPRESSION OF MRP2 (ABCC2) IN HUMAN PLACENTA: INFLUENCE OF GESTATIONAL AGE AND CELLULAR DIFFERENTIATION. Drug Metabolism and Disposition, 2005, 33, 896-904.	3.3	144
24	CYP1A1 T3801 C polymorphism and lung cancer: A pooled analysis of 2,451 cases and 3,358 controls. International Journal of Cancer, 2003, 104, 650-657.	5.1	140
25	MDR1 genotypes do not influence the absorption of a single oral dose of 1â€ƒmg digoxin in healthy white males. British Journal of Clinical Pharmacology, 2002, 54, 610-616.	2.4	133
26	Candidate Gene Analysis Identifies a Polymorphism inHLA-DQB1Associated With Clozapine-Induced Agranulocytosis. Journal of Clinical Psychiatry, 2011, 72, 458-463.	2.2	124
27	Transient Receptor Potential Channel Polymorphisms Are Associated with the Somatosensory Function in Neuropathic Pain Patients. PLoS ONE, 2011, 6, e17387.	2.5	123
28	Drug Interactions. Deutsches Ärzteblatt International, 2012, 109, 546-55; quiz 556.	0.9	122
29	Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1337-1354.	3.3	119
30	CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clinical Pharmacology and Therapeutics, 2004, 75, 213-222.	4.7	118
31	CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients. Clinical Pharmacology and Therapeutics, 2007, 81, 228-234.	4.7	118
32	Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis, 2001, 22, 453-459.	2.8	110
33	Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. International Journal of Epidemiology, 2003, 32, 60-63.	1.9	109
34	Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochemical Pharmacology, 1999, 58, 1759-1764.	4.4	103
35	Expression and Localization of P-glycoprotein in Human Heart. Journal of Histochemistry and Cytochemistry, 2002, 50, 1351-1356.	2.5	101
36	Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes and Control, 2003, 14, 339-346.	1.8	98

#	Article	IF	Citations
37	Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics Journal, 2005, 5, 365-373.	2.0	97
38	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. Gastroenterology, 2019, 156, 1707-1716.e2.	1.3	97
39	A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS ONE, 2016, 11, e0162866.	2.5	96
40	Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphateâ€“glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clinical Pharmacology and Therapeutics, 2006, 79, 206-217.	4.7	94
41	Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3?-flanking region. The Clinical Investigator, 1994, 72, 240-8.	0.6	92
42	Expression and Localization of the Multidrug Resistance Protein 5 (MRP5/ABCC5), a Cellular Export Pump for Cyclic Nucleotides, in Human Heart. American Journal of Pathology, 2003, 163, 1567-1577.	3.8	89
43	The Nomenclature, Definition and Distinction of Types of Shock. Deutsches Ärzteblatt International, 2018, 115, 757-768.	0.9	89
44	The ATP-binding Cassette Transporter ABCG2 (BCRP), a Marker for Side Population Stem Cells, Is Expressed in Human Heart. Journal of Histochemistry and Cytochemistry, 2006, 54, 215-221.	2.5	88
45	Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 â^'24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenetics and Genomics, 2009, 19, 353-362.	1.5	87
46	A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet, The, 1999, 353, 708-712.	13.7	84
47	ARYLAMINEN-ACETYLTRANSFERASE ACTIVITY IN MAN. Drug Metabolism Reviews, 1999, 31, 489-502.	3.6	81
48	Genetic basis of toxic reactions to drugs and chemicals. Toxicology Letters, 2006, 162, 16-28.	0.8	79
49	Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenetics and Genomics, 2008, 18, 357-365.	1.5	76
50	Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics and Genomics, 2004, 14, 381-385.	5.7	75
51	Micro<scp>RNA</scp>s and their relevance to <scp>ABC</scp> transporters. British Journal of Clinical Pharmacology, 2014, 77, 587-596.	2.4	75
52	Down-Regulation of ATP-Binding Cassette C2 Protein Expression in HepG2 Cells after Rifampicin Treatment Is Mediated by MicroRNA-379. Molecular Pharmacology, 2011, 80, 314-320.	2.3	74
53	Hematopoietic stem cell involvement in BCR-ABL1â€“positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood, 2017, 130, 2027-2031.	1.4	72
54	MicroRNA profiling in K-562 cells under imatinib treatment. Pharmacogenetics and Genomics, 2012, 22, 198-205.	1.5	70

#	Article	IF	Citations
55	A LCâ€“MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 830, 143-150.	2.3	68
56	Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics Journal, 2011, 11, 25-34.	2.0	68
57	High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics and Genomics, 2000, 10, 133-140.	5.7	66
58	Genetic Determinants of Clozapine-Induced Agranulocytosis: Recent Results of HLA Subtyping in a Non-Jewish Caucasian Sample. Archives of General Psychiatry, 2001, 58, 93.	12.3	66
59	Molecular Genetics of Cancer Susceptibility. Pharmacology, 2000, 61, 212-227.	2.2	65
60	Decreased Levels of Dopamine D₃ Receptor mRNA in Schizophrenic and Bipolar Patients. Neuropsychobiology, 2004, 50, 305-310.	1.9	65
61	Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. Pharmacogenomics, 2019, 20, 643-657.	1.3	65
62	High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: comparison with lung parenchyma. Cancer Letters, 2004, 207, 157-163.	7.2	64
63	HLA-DRB1*16. Pharmacogenetics and Genomics, 2016, 26, 218-224.	1.5	63
64	miRNAs as mediators of drug resistance. Epigenomics, 2012, 4, 369-381.	2.1	62
65	Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics and Genomics, 1999, 9, 123.	5.7	61
66	Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics and Genomics, 2001, 11, 135-141.	5.7	59
67	Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics Journal, 2007, 7, 325-332.	2.0	58
68	Impact of Myeloperoxidase and NADPH-Oxidase Polymorphisms in Drug-Induced Agranulocytosis. Journal of Clinical Psychopharmacology, 2004, 24, 613-617.	1.4	55
69	Pharmacogenetics of ATP-Binding Cassette Transporters and Clinical Implications. Methods in Molecular Biology, 2010, 596, 95-121.	0.9	54
70	Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1). Clinical Cancer Research, 2014, 20, 985-994.	7.0	54
71	Clinical trial: A novel high-dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflammatory Bowel Diseases, 2010, 16, 1947-1956.	1.9	53
72	OpenVigilâ€”free eyeballs on AERS pharmacovigilance data. Nature Biotechnology, 2012, 30, 137-138.	17.5	53

#	Article	IF	Citations
73	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics and Genomics, 2000, 10, 519-530.	5.7	52
74	The Neurophysiology and Treatment of Motion Sickness. Deutsches Ärzteblatt International, 2018, 115, 687-696.	0.9	52
75	Occupational history and genetic N-acetyltransferase polymorphism of urothelial cancer patients in Leverkusen, Germany. Scandinavian Journal of Work, Environment and Health, 1996, 22, 332-338.	3.4	51
76	Metabolic gene polymorphisms and lung cancer risk in non-smokers. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 592, 45-57.	1.0	50
77	Antimicrobial peptides and proteins of the horse - insights into a well-armed organism. Veterinary Research, 2011, 42, 98.	3.0	50
78	Polymorphisms in xenobiotic conjugation and disease predisposition. Toxicology Letters, 1998, 102-103, 173-183.	0.8	49
79	Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics and Genomics, 1999, 9, 103???112.	5.7	49
80	Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease. Atherosclerosis, 2001, 154, 651-658.	0.8	48
81	Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. Oncology Research and Treatment, 2020, 43, 628-636.	1.2	48
82	Mutations in the human paraoxonase 1 gene. Pharmacogenetics and Genomics, 1999, 9, 755-762.	5.7	47
83	Myeloperoxidase G-463A polymorphism and lung cancer: A HuGE Genetic Susceptibility to Environmental Carcinogens pooled analysis. Genetics in Medicine, 2007, 9, 67-73.	2.4	47
84	Elimination Half-Life of Anti-MÃ¼llerian Hormone. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2160-2163.	3.6	47
85	Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. Clinical Pharmacology and Therapeutics, 2018, 104, 317-325.	4.7	46
86	Myeloperoxidase â€“ 463A variant reduces benzo[a]pyrene diol epoxide DNA adducts in skin of coal tar treated patients. Carcinogenesis, 2001, 22, 1015-1018.	2.8	45
87	Effect of levothyroxine administration on intestinal P-glycoprotein expression: Consequences for drug disposition*. Clinical Pharmacology and Therapeutics, 2002, 72, 256-264.	4.7	45
88	Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the Î² 2 -adrenergic receptor among Turks. British Journal of Clinical Pharmacology, 1999, 48, 761-764.	2.4	44
89	Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. Pharmacogenomics, 2009, 10, 1941-1953.	1.3	44
90	Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenetics and Genomics, 2011, 21, 624-630.	1.5	44

#	Article	IF	Citations
91	Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. BMC Cancer, 2013, 13, 617.	2.6	43
92	Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus. Therapeutic Drug Monitoring, 2015, 37, 288-295.	2.0	42
93	Clozapine-induced Agranulocytosis and Hereditary Polymorphisms of Clozapine Metabolizing Enzymes: No Association with Myeloperoxidase and Cytochrome P4502D6. Pharmacopsychiatry, 2000, 33, 218-220.	3.3	41
94	Gender and smoking-related risk reduction of periodontal disease with variant myeloperoxidase alleles. Genes and Immunity, 2002, 3, 102-106.	4.1	41
95	Dysregulation of Mucosal Membrane Transporters and Drug-Metabolizing Enzymes in Ulcerative Colitis. Journal of Pharmaceutical Sciences, 2019, 108, 1035-1046.	3.3	41
96	Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. British Journal of Clinical Pharmacology, 2006, 61, 440-450.	2.4	40
97	Functional significance of a hereditary adenine insertion variant in the 5???-UTR of the endothelin-1 gene. Pharmacogenetics and Genomics, 2003, 13, 445-451.	5.7	39
98	Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia, 2008, 49, 1555-1561.	5.1	39
99	Association of ATP-binding cassette transporter variants with the risk of Alzheimerâ€™s disease. Pharmacogenomics, 2013, 14, 485-494.	1.3	39
100	Pharmacovigilanceâ€based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. British Journal of Clinical Pharmacology, 2021, 87, 4421-4431.	2.4	39
101	High frequency of CYP1A1 mutations in a Turkish population. Archives of Toxicology, 1998, 72, 215-218.	4.2	38
102	SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients. Neurobiology of Disease, 2015, 77, 127-140.	4.4	38
103	Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clinical Pharmacology and Therapeutics, 1996, 59, 376-382.	4.7	37
104	Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions. Pharmacological Research, 2020, 161, 105250.	7.1	37
105	ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 369-396.	3.3	37
106	Endothelial NO Synthase Polymorphisms and Postural Tachycardia Syndrome. Hypertension, 2005, 46, 1103-1110.	2.7	36
107	Identification and Characterization of a Defective CYP3A4 Genotype in a Kidney Transplant Patient With Severely Diminished Tacrolimus Clearance. Clinical Pharmacology and Therapeutics, 2014, 95, 416-422.	4.7	36
108	Interaction of herbal products with prescribed medications: A systematic review and meta-analysis. Pharmacological Research, 2019, 141, 397-408.	7.1	36

#	Article	IF	Citations
109	Drug Hypersensitivity: Diagnosis, Genetics, and Prevention. Deutsches Ärzteblatt International, 2018, 115, 501-512.	0.9	35
110	N-Acetyltransferase 2 (NAT2) and Glutathione S-Transferase Î¼ (GSTM1) in Bladder-cancer Patients in a Highly Industrialized Area. International Journal of Occupational and Environmental Health, 1997, 3, 105-110.	1.2	34
111	Genetic Determinants of Drug-Induced Agranulocytosis: Potential Risk of Olanzapine?. Pharmacopsychiatry, 1999, 32, 110-112.	3.3	34
112	Paraoxonase 1 Mutations in a Turkish Population. Toxicology and Applied Pharmacology, 1999, 157, 174-177.	2.8	34
113	How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport. Clinical Chemistry and Laboratory Medicine, 2000, 38, 869-76.	2.3	34
114	Role of Kozak sequence polymorphism of platelet glycoprotein IbÎ± as a risk factor for coronary artery disease and catheter interventions. Journal of the American College of Cardiology, 2001, 38, 1023-1027.	2.8	34
115	Pharmacogeneticsâ€Based New Therapeutic Concepts. Drug Metabolism Reviews, 2004, 36, 617-638.	3.6	32
116	Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions. Frontiers in Pharmacology, 2016, 7, 396.	3.5	32
117	NAT2*12A (803A???G) codes for rapid arylamine N-acetylatioii in humans. Pharmacogenetics and Genomics, 1996, 6, 257-259.	5.7	31
118	Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine. Molecular Pharmaceutics, 2017, 14, 2245-2253.	4.6	31
119	Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. Pharmacogenetics and Genomics, 1997, 7, 327-331.	5.7	30
120	Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample. Journal of Hypertension, 2005, 23, 1361-1366.	0.5	30
121	Implementation and obstacles of pharmacogenetics in clinical practice: An international survey. British Journal of Clinical Pharmacology, 2019, 85, 2076-2088.	2.4	30
122	CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping. Pharmacogenetics and Genomics, 1997, 7, 303-307.	5.7	29
123	Influence of CYP3A4, CYP3A5, and ABCB1 Genotype and Expression on Budesonide Pharmacokinetics: A Possible Role of Intestinal CYP3A4 Expression. Clinical Pharmacology and Therapeutics, 2008, 84, 43-46.	4.7	29
124	ABC Transporters in Drug-Refractory Epilepsy: Limited Clinical Significance of Pharmacogenetics?. Clinical Pharmacology and Therapeutics, 2010, 87, 15-18.	4.7	29
125	Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human NADPH-cytochrome P450 reductase in the baculovirus/ insect cell system. Xenobiotica, 2001, 31, 345-356.	1.1	28
126	Differential Expression and Functionality of TRPA1 Protein Genetic Variants in Conditions of Thermal Stimulation. Journal of Biological Chemistry, 2012, 287, 27087-27094.	3.4	28

#	Article	IF	Citations
127	Genetic variants may play an important role in mRNAâ€“miRNA interaction. Pharmacogenetics and Genomics, 2014, 24, 283-291.	1.5	28
128	Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. Pharmacogenetics and Genomics, 1996, 6, 535-545.	5.7	27
129	Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. Pharmacogenetics and Genomics, 2002, 12, 559-563.	5.7	27
130	Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. European Journal of Clinical Pharmacology, 2012, 68, 389-395.	1.9	25
131	Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine. Molecular Pharmaceutics, 2019, 16, 3823-3830.	4.6	24
132	Endothelial nitric oxide synthase Glu298â†'Asp polymorphism, carotid atherosclerosis and intima-media thickness in a general population sample. Clinical Science, 2005, 109, 475-481.	4.3	23
133	Expression differences of miR-142-5p between treatment-naÃ¯ve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance. Experimental Hematology and Oncology, 2020, 9, 26.	5.0	23
134	Correlation between the lipophilicity of substituted phenols and their inhibition of the Na+/K+-ATPase of Chinese hamster ovary cells. Toxicology, 1989, 58, 197-210.	4.2	22
135	Interaction of xenobiotics on the glucose-transport system and the of human skin fibroblasts. Ecotoxicology and Environmental Safety, 1991, 21, 38-46.	6.0	22
136	Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. International Journal of Cancer, 2004, 110, 266-270.	5.1	21
137	â€˜Comparison of extremesâ€™ approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility. Cancer Letters, 2005, 221, 177-183.	7.2	21
138	Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 207-214.	2.3	21
139	miRNA-187-3p-Mediated Regulation of the KCNK10/TREK-2 Potassium Channel in a Rat Epilepsy Model. ACS Chemical Neuroscience, 2016, 7, 1585-1594.	3.5	21
140	Elevated serum leptin in patients with coronary artery disease: no association with the Trp64Arg polymorphism of the Î²3-adrenergic receptor. International Journal of Obesity, 2000, 24, 369-375.	3.4	20
141	Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. Journal of the American College of Cardiology, 2000, 36, 1520-1525.	2.8	20
142	Epigenetics in Drug Response. Clinical Pharmacology and Therapeutics, 2016, 99, 468-470.	4.7	20
143	Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia. Frontiers in Pharmacology, 2021, 12, 696960.	3.5	20
144	Association between the Nâ€acetylation genetic polymorphism and bronchial asthma. British Journal of Clinical Pharmacology, 2002, 54, 671-674.	2.4	19

#	Article	IF	Citations
145	Pharmacogenomics of heart failure - focus on drug disposition and action*1. Cardiovascular Research, 2004, 64, 32-39.	3.8	19
146	The promises of personalized medicine. European Journal of Clinical Pharmacology, 2010, 66, 749-754.	1.9	19
147	Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. Pharmacogenomics, 2016, 17, 367-374.	1.3	19
148	Length variants of the ABCB1 3â€²-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance. Pharmacogenomics, 2016, 17, 327-340.	1.3	19
149	Pharmacogenomic or â€epigenomic biomarkers in drug treatment: Two sides of the same medal?. Clinical Pharmacology and Therapeutics, 2016, 99, 478-480.	4.7	18
150	MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells. Oncotarget, 2017, 8, 92018-92031.	1.8	18
151	Co-trimoxazole-induced liver and renal failure. European Journal of Clinical Pharmacology, 2000, 56, 191-193.	1.9	17
152	Phenotyping of N -acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. European Journal of Clinical Pharmacology, 2004, 60, 17-21.	1.9	17
153	Short Report: TRPV1-polymorphism 1911 A>G alters capsaicin-induced sensory changes in healthy subjects. PLoS ONE, 2017, 12, e0183322.	2.5	17
154	Effects of a Heterogenous Set of Xenobiotics on Growth and Plasma Membranes of Mammalian and Fungal Cell Cultures. Ecotoxicology and Environmental Safety, 1993, 26, 113-126.	6.0	16
155	Genotype Frequencies of Selected Drug Metabolizing Enzymes and ABC Drug Transporters among Breast Cancer Patients on FAC Chemotherapy. Basic and Clinical Pharmacology and Toxicology, 2010, 107, 570-576.	2.5	16
156	Overlapping effects of genetic variation and epigenetics on drug response: challenges of pharmacoepigenomics. Pharmacogenomics, 2013, 14, 1807-1809.	1.3	16
157	The serotonin receptor 2A (HTR2A) rs6313 variant is associated with higher ongoing pain and signs of central sensitization in neuropathic pain patients. European Journal of Pain, 2021, 25, 595-611.	2.8	16
158	Expression of N-acetyltransferases in Periodontal Granulation Tissue. Journal of Dental Research, 2002, 81, 349-353.	5.2	15
159	Major Increase of Quetiapine Steady-State Plasma Concentration Following Co-Administration of Clarithromycin: Confirmation of the Pharmacokinetic Interaction Potential of Quetiapine. Pharmacopsychiatry, 2008, 41, 258-259.	3.3	15
160	Alternative Polyadenylation of ABC Transporters of the C-Family (ABCC1, ABCC2, ABCC3) and Implications on Posttranscriptional Micro-RNA Regulation. Molecular Pharmacology, 2020, 97, 112-122.	2.3	15
161	Drug-Induced Agranulocytosis. Journal of Clinical Psychopharmacology, 2005, 25, 435-440.	1.4	14
162	Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes. Pharmacogenetics and Genomics, 2007, 17, 77-83.	1.5	14

#	Article	IF	Citations
163	A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. European Journal of Clinical Investigation, 2007, 37, 558-565.	3.4	14
164	Functional Characterization of Protein Variants Encoded by Nonsynonymous Single Nucleotide Polymorphisms inMARC1andMARC2in Healthy Caucasians. Drug Metabolism and Disposition, 2014, 42, 718-725.	3.3	14
165	Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population. Scientific Reports, 2019, 9, 7323.	3.3	14
166	Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Allows Allelic Allocation ofCYP1A1Mutations. Analytical Biochemistry, 1997, 250, 256-257.	2.4	13
167	The Î²3-adrenergic receptor Trp64Arg mutation is not associated with coronary artery disease. Metabolism: Clinical and Experimental, 2001, 50, 184-188.	3.4	13
168	No benefit of 3,4-diaminopyridine in essential tremor: A placebo-controlled crossover study. Neurology, 2006, 66, 1753-1755.	1.1	13
169	Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method. Chemico-Biological Interactions, 2011, 191, 104-112.	4.0	13
170	Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010. Pharmacogenomics, 2011, 12, 1051-1059.	1.3	13
171	Retinoic acidâ€“induced survival effects in SHâ€SY5Y neuroblastoma cells. Journal of Cellular Biochemistry, 2019, 120, 5974-5986.	2.6	13
172	Drugâ€Drugâ€Gene Interactions: A Call for Clinical Consideration. Clinical Pharmacology and Therapeutics, 2021, 110, 549-551.	4.7	13
173	A1166C polymorphism of the angiotensin II type 1 receptor gene and risk of adverse events after coronary catheter interventions. American Heart Journal, 2000, 140, 170-175.	2.7	12
174	Identification and functional analysis of genetic variants of the human ??-glucuronidase in a German population sample. Pharmacogenetics and Genomics, 2005, 15, 875-881.	1.5	12
175	Challenges in pharmacogenetics. European Journal of Clinical Pharmacology, 2013, 69, 17-23.	1.9	12
176	Progress in Pharmacogenomics: Bridging the Gap From Research to Practice. Clinical Pharmacology and Therapeutics, 2014, 95, 231-235.	4.7	12
177	Beta 2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma. European Journal of Clinical Pharmacology, 2003, 59, 527-531.	1.9	11
178	Neurodegenerative effects of azithromycin in differentiated PC12 cells. European Journal of Pharmacology, 2017, 809, 1-12.	3.5	11
179	Significance of Pharmacogenomics in Precision Medicine. Clinical Pharmacology and Therapeutics, 2018, 103, 732-735.	4.7	11
180	Influence of an Insertion Variant in the 5Ê¹UTR of the Endothelin-1 Gene on Orthostatic Intolerance. American Journal of the Medical Sciences, 2005, 330, 166-171.	1.1	10

#	Article	IF	Citations
181	Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network. Journal of Community Genetics, 2019, 10, 523-530.	1.2	10
182	SIGMA-1 Receptor Gene Variants Affect the Somatosensory Phenotype in Neuropathic Pain Patients. Journal of Pain, 2019, 20, 201-214.	1.4	10
183	Interaction of CA repeat polymorphism of the endothelial nitric oxide synthase and hyperhomocysteinemia in acute coronary syndromes: evidence of gender-specific differences. Journal of Molecular Medicine, 2003, 81, 305-309.	3.9	9
184	Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 949-959.	3.0	9
185	MicroRNA-655-3p regulates Echinacea purpurea mediated activation of ABCG2. Xenobiotica, 2018, 48, 1050-1058.	1.1	9
186	Hyperhomocysteinaemia and adverse events complicating coronary catheter interventions. International Journal of Cardiology, 2000, 76, 211-217.	1.7	8
187	Identification of Twelve Polymorphisms in the Endothelin-1 Gene by Use of Fluorescently Labeled Oligonucleotides and PCR with Restriction Fragment Polymorphism Analysis. Clinical Chemistry, 2004, 50, 448-451.	3.2	8
188	Inflammation: Treatment Progress and Limitations. Clinical Pharmacology and Therapeutics, 2017, 102, 564-567.	4.7	8
189	Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor Î³-independent mechanism. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 37-48.	3.0	8
190	Activation of the cell membrane angiotensin AT2 receptors in human leiomyosarcoma cells induces differentiation and apoptosis by a PPARÎ³ â€“ dependent mechanism. Neoplasma, 2017, 64, 395-405.	1.6	8
191	Opportunities and limitations: the value of pharmacogenetics in clinical practice. British Journal of Clinical Pharmacology, 2014, 77, 583-586.	2.4	7
192	Advances and challenges in hereditary cancer pharmacogenetics. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 73-82.	3.3	7
193	The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions. Blood, 2000, 96, 2002-2003.	1.4	6
194	A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis. Thrombosis and Haemostasis, 2005, 93, 180-182.	3.4	6
195	A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. Investigational New Drugs, 2013, 31, 661-668.	2.6	6
196	Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. Liver International, 2006, 26, 285-290.	3.9	5
197	Gliflozins for the treatment of congestive heart failure and renal failure in type 2 diabetes. Deutsches Ärzteblatt International, 2021, 118, .	0.9	5
198	Interaction of Phytocompounds of Echinacea purpurea with ABCB1 and ABCG2 Efflux Transporters. Molecular Pharmaceutics, 2021, 18, 1622-1633.	4.6	5

#	Article	IF	Citations
199	The Uncertainties of Metamizole Use. Clinical Pharmacology and Therapeutics, 2021, 109, 1373-1375.	4.7	5
200	Pharmacogenomics in acute coronary syndrome. Expert Opinion on Pharmacotherapy, 2008, 9, 363-376.	1.8	4
201	Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: An open-label, prospective study of long-term administration in adults. Clinical Therapeutics, 2010, 32, 347-356.	2.5	4
202	Targeting gene expression during the early bone healing period in the mandible: A base for bone tissue engineering. Journal of Cranio-Maxillo-Facial Surgery, 2015, 43, 1452-1460.	1.7	4
203	The Pharmacogenetics of Immune-Modulating Therapy. Advances in Pharmacology, 2018, 83, 275-296.	2.0	4
204	Plan S: A threat to quality of science?. Science, 2019, 363, 462-462.	12.6	4
205	ZFP36L1 plays an ambiguous role in the regulation of cell expansion and negatively regulates CDKN1A in chronic myeloid leukemia cells. Experimental Hematology, 2021, 99, 54-64.e7.	0.4	4
206	Involvement of medical students in aÂsurgery congress: impact on learning motivation, decision-making for aÂcareer in surgery, and educational curriculum. Wiener Medizinische Wochenschrift, 2021, 171, 182-193.	1.1	3
207	Limited Impact of 6-Mercaptopurine on Inflammation-Induced Chemokines Expression Profile in Primary Cultures of Enteric Nervous System. Neurochemical Research, 2021, 46, 1781-1793.	3.3	3
208	Influence of doxorubicin on gene expression and protein pattern in HeLa cells. International Journal of Clinical Pharmacology and Therapeutics, 2004, 42, 640-641.	0.6	3
209	Germline variants in cancer therapy. , 2019, 2, 18-30.		3
210	Effects of a Heterogeneous Set of Xenobiotics on RNA Synthesis of Yeast Cells. Ecotoxicology and Environmental Safety, 1995, 30, 252-258.	6.0	2
211	Pharmacological Treatment of Pain: Future Trends and Novel Insights. Clinical Pharmacology and Therapeutics, 2015, 97, 104-108.	4.7	2
212	Highâ€dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT). European Journal of Pain, 2021, 25, 1739-1750.	2.8	2
213	Progress and Challenges in Pharmacogenomics. Clinical Pharmacology and Therapeutics, 2021, 110, 529-532.	4.7	2
214	A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis. Thrombosis and Haemostasis, 2005, 93, 180-2.	3.4	2
215	Implication of arylamine N-acetyltransferase (NAT2) polymorphism on levels of tumour markers CEA, AFP, CA 125, CA 19.9, and CA 15.3. Biomarkers, 1999, 4, 129-134.	1.9	1
216	Safe and effective medicines for all: is personalized medicine the answer?. Expert Review of Clinical Pharmacology, 2010, 3, 627-637.	3.1	1

#	Article	IF	Citations
217	Crosstalk control and limits of physiological c-Jun N-terminal kinase activity for cell viability and neurite stability in differentiated PC12 cells. Molecular and Cellular Neurosciences, 2017, 82, 12-22.	2.2	1
218	4th ESPT Conference: pharmacogenomics and personalized medicineÂâ€“ research progress and clinical implementation. Pharmacogenomics, 2019, 20, 1063-1069.	1.3	1
219	Neue Fortbildungsreihe zur Notfallpharmakotherapie. Notfall Und Rettungsmedizin, 2020, 23, 450-451.	0.3	1
220	Pharmakodynamik. , 2011, , 15-43.		1
221	Replication of Genetic Markers Associated with Clozapine-Induced Agranulocytosis.. Blood, 2006, 108, 1280-1280.	1.4	1
222	Sao Paulo Research Conference on Molecular Medicine and Pharmacogenetics, A Joint Meeting with the IUPHAR Sub-Committee on Pharmacogenetics and the Brazilian Pharmacogenetics Network, Sao Paulo, Brazil, September 18-20, 2008. Current Pharmacogenomics and Personalized Medicine, 2008, 6, 234-238.	0.2	1
223	Abstract 5846: Drug resistance in chronic myeloid leukemia: Impact of methylation on gene expression in imatinib and nilotinib resistance. , 2018, , .		1
224	The G protein subunit Î²3 and early complications after coronary catheter interventions. Atherosclerosis, 2000, 153, 523-524.	0.8	0
225	OV-A-2Inducibility of UGT1A1 mrna is dependent on UGT1A1âž28 genotype. Clinical Pharmacology and Therapeutics, 2006, 79, P34-P34.	4.7	0
226	Research Highlights: Highlights from the latest articles in breast cancer pharmacogenomics. Pharmacogenomics, 2012, 13, 645-649.	1.3	0
227	TRP Gene Polymorphism and DiseaseÂRisk. , 2015, , 59-87.		0
228	P0180 Effect of pioglitazone on proliferation and apoptosis in human uterine leiomyosarcoma cells. European Journal of Cancer, 2015, 51, e34.	2.8	0
229	Challenges in Neuropharmacology. Clinical Pharmacology and Therapeutics, 2019, 105, 1050-1053.	4.7	0
230	The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions. Blood, 2000, 96, 2002-2003.	1.4	0
231	Molecular-epidemiological aspects of carcinogenesis: the role of xenobiotic metabolizing enzymes. International Journal of Clinical Pharmacology and Therapeutics, 2002, 40, 562-563.	0.6	0
232	CYP1A1 alleles in women with focal nodular hyperplasia of the liver (FNH). International Journal of Clinical Pharmacology and Therapeutics, 2004, 42, 78-82.	0.6	0
233	A UK problem. BMJ: British Medical Journal, 2008, 337, a2919-a2919.	2.3	0
234	Abstract 1097: MicroRNA expression in white blood cells of CML patients: Differential expression in responders and non-responders to imatinib. , 2012, , .		0

#	Article	IF	Citations
235	In Reply. Deutsches Ärzteblatt International, 2013, 110, 133.	0.9	0
236	In Reply. Deutsches Ärzteblatt International, 2018, 115, 713.	0.9	0
237	Neonatale Pharmakologie. , 2005, , 643-659.		0